EP1192263B1 - Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator - Google Patents
Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator Download PDFInfo
- Publication number
- EP1192263B1 EP1192263B1 EP00944702A EP00944702A EP1192263B1 EP 1192263 B1 EP1192263 B1 EP 1192263B1 EP 00944702 A EP00944702 A EP 00944702A EP 00944702 A EP00944702 A EP 00944702A EP 1192263 B1 EP1192263 B1 EP 1192263B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- gene
- promoter
- methanolica
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241001452677 Ogataea methanolica Species 0.000 title claims abstract description 69
- 101710162682 Glyceraldehyde-3-phosphate dehydrogenase 1 Proteins 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 82
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 238000013518 transcription Methods 0.000 claims abstract description 22
- 230000035897 transcription Effects 0.000 claims abstract description 22
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000003248 secreting effect Effects 0.000 claims description 14
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 12
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims description 4
- 101500023488 Lithobates catesbeianus GnRH-associated peptide 1 Proteins 0.000 abstract description 19
- 101150110969 gap1 gene Proteins 0.000 abstract description 12
- 239000013604 expression vector Substances 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 108700007698 Genetic Terminator Regions Proteins 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 44
- 239000012634 fragment Substances 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 101150029183 PEP4 gene Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 102000005572 Cathepsin A Human genes 0.000 description 8
- 108010059081 Cathepsin A Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- BBXRRTJNJCPGBU-UHFFFAOYSA-N beta-naphthyl N-acetylphenylalaninate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)C(NC(=O)C)CC1=CC=CC=C1 BBXRRTJNJCPGBU-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 101150096273 ADE2 gene Proteins 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 5
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 101150112014 Gapdh gene Proteins 0.000 description 5
- 241000235058 Komagataella pastoris Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 101150101314 PRB1 gene Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101001091368 Rattus norvegicus Glandular kallikrein-7, submandibular/renal Proteins 0.000 description 4
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108010078692 yeast proteinase B Proteins 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CJERUMAUMMIPRF-FQEVSTJZSA-N n-[(2s)-3-(4-hydroxyphenyl)-1-(4-nitroanilino)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(O)=CC=C1C[C@@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)C1=CC=CC=C1 CJERUMAUMMIPRF-FQEVSTJZSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108010082737 zymolyase Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 101150034952 AUG1 gene Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- PUDCZUQFOPHIGU-UHFFFAOYSA-N [2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]azanium;chloride Chemical compound Cl.C1=C(N)C(C)=CC(N=NC=2C(=CC=CC=2)C)=C1 PUDCZUQFOPHIGU-UHFFFAOYSA-N 0.000 description 1
- PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- PPTXFSQSISUDAU-UHFFFAOYSA-M hydrogen sulfate;2-methyl-4-[(2-methylphenyl)diazenyl]benzenediazonium Chemical compound OS([O-])(=O)=O.CC1=CC=CC=C1N=NC1=CC=C([N+]#N)C(C)=C1 PPTXFSQSISUDAU-UHFFFAOYSA-M 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052603 melanterite Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000005365 phosphate glass Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
Definitions
- Methylotrophic yeasts are those yeasts that are able to utilize methanol as a sole source of carbon and energy. Species of yeast that have the biochemical pathways necessary for methanol utilization are classified in four genera, Hansenula, Pichia, Candida, and Torulopsis. These genera are somewhat artificial, having been based on cell morphology and growth characteristics, and do not reflect close genetic relationships (Billion-Grand, Mycotaxon 35 :201-204, 1989; Kurtzman, Mycologia 84 :72-76, 1992). Furthermore, not all species within these genera are capable of utilizing methanol as a source of carbon and energy. As a consequence of this classification, there are great differences in physiology and metabolism between individual species of a genus.
- Methylotrophic yeasts are attractive candidates for use in recombinant protein production systems for several reasons.
- WO-A-99/14347 discloses a method for producing proteins heterologous to Pichia methanolica in a protease deficient Pichia methanolica cell.
- WO-A-97/17450 discloses a method for producing proteins heterologous to P. methanolica by utilising a methanol-inducible promoter (Alcohol Utilisation Gene 1, SEQ ID No: 2) in a P. methanolica cell.
- EP-A-0374913 discloses the Pichia pastoris glyceraldehyde 3-phosphate dehydrogenase gene.
- EP-A-0438200 discloses a method of producing proteins heterologous to P. pastoris by utilising an endogenous Alcohol Oxidase (AOX 1 ) promoter in a P . pastoris cell.
- AOX 1 Alcohol Oxidase
- Genbank, Ace. No. U95625 discloses the sequence of the P. angusta glyceraldehyde 3-phosphate dehydrogenase gene.
- methanol-inducible transcription promoters Previously described expression systems for methylotrophic yeasts rely largely on the use of methanol-inducible transcription promoters.
- the use of methanol-induced promoters is, however, problematic as production is scaled up to commercial levels.
- the overall volume of methanol used during the fermentation process can be as much as 40% of the final fermentation volume, and at 1000-liter fermentation scale and above the volumes of methanol required for induction necessitate complex and potentially expensive considerations.
- the present invention provides an isolated DNA molecule of up to 1500 nucleotides in length comprising nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.
- a DNA construct comprising the following operably linked elements: a first DNA segment comprising at least a portion of the sequence of SEQ ID NO:1 from nucleotide 733 to nucleotide 1732, wherein the portion is a functional transcription promoter; a second DNA segment encoding a protein of interest other than a Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase; and a third DNA segment comprising a transcription terminator.
- the first DNA segment is from 900 to 1500 nucleotides in length.
- the first DNA segment is from 900 to 1000 nucleotides in length.
- the first DNA segment comprises nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.
- the first DNA segment is essentially free of DNA encoding a P . methanolica glyceraldehyde-3-phosphate dehydrogenase.
- the DNA construct may further comprise a selectable marker, such as a P. methanolica gene, for example a P . methanolica ADE2 gene.
- the DNA construct may be a closed, circular molecule or a linear molecule.
- the DNA constuct further comprises a secretory signal sequence, such as a Saccharomyces cerevisiae alpha-factor pre-pro sequence, operably linked to the first and second DNA segments.
- the third DNA segment comprises a transcription terminator of a P . methanolica AUG1 or GAP1 gene.
- a P. methanolica cell containing a DNA construct as disclosed above.
- the DNA construct is genomically integrated.
- the DNA construct is genomically integrated in multiple copies.
- the P . methanolica cell is functionally deficient in vacuolar proteases proteinase A and proteinase B.
- a method of producing a protein of interest comprising the steps of (a) culturing a P. methanolica cell as disclosed above whereby the second DNA segment is expressed and the protein of interest is produced, and (b) recovering the protein of interest.
- a DNA construct comprising the following operably linked elements: a first DNA segment comprising a P. methanolica gene transcription promoter; a second DNA segment encoding a protein of interest other than a P. methanolica protein; and a third DNA segment comprising nucleotides 2735 to 2795 of SEQ ID NO:1.
- allelic variant is used herein to denote an alternative form of a gene. Allelic variation is known to exist in populations and arises through mutation.
- a "DNA construct” is a DNA molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of DNA combined and juxtaposed in an arrangement not existing in nature.
- a "DNA segment” is a portion of a larger DNA molecule having specified attributes.
- a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, that, when read from the 5' to the 3' direction, encodes the sequence of amino acids of the specified polypeptide.
- the term "functionally deficient” denotes the expression in a cell of less than 10% of an activity as compared to the level of that activity in a wild-type counterpart. Often the expression level will be less than 1% of the activity in the wild-type counterpart, frequently less than 0.01% as determined by appropriate assays. In some instances it is desirable that the activity be essentially undetectable (i.e., not significantly above background). Functional deficiencies in genes can be generated by mutations in either coding or non-coding regions.
- gene is used herein to denote a DNA segment encoding a polypeptide. Where the context allows, the term includes genomic DNA (with or without intervening sequences), cDNA, and synthetic DNA. Genes may include non-coding sequences, including promoter elements.
- isolated when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.
- isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones.
- “Operably linked”, when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.
- polynucleotide is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end.
- Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt”), or kilobases ("kb”). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded.
- base pairs When these terms are applied to double-stranded molecules they are used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.
- polypeptide is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides”.
- promoter is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes. Sequences within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, and transcription factor binding sites. Of particular interest within the present invention are Gcrlp binding sites, characterized by the consensus sequences CTTCC or GGAAG, and Rap1p binding sites. See, in general, Watson et al., eds., Molecular Biology of the Gene , 4th ed., The Benjamin/Cummings Publishing Company, Inc., Menlo Park, CA, 1987.
- pro sequence is a DNA sequence that commonly occurs immediately 5' to the mature coding sequence of a gene encoding a secretory protein.
- the pro sequence encodes a pro peptide that serves as a cis-acting chaperone as the protein moves through the secretory pathway.
- a “protein” is a macromolecule comprising one or more polypeptide chains.
- a protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are commonly defined in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
- secretory signal sequence denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized.
- the larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.
- a secretory peptide and a pro peptide may be collectively referred to as a pre-pro peptide.
- the present invention provides isolated DNA molecules comprising a Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene promoter.
- the invention also provides isolated DNA molecules comprising a P. methanolica GAPDH gene terminator.
- the promoter and terminator can be used within methods of producing proteins of interest, including proteins of pharmaceutical or industrial value.
- SEQ ID NO:1 The sequence of a DNA molecule comprising a P. methanolica glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene promoter, coding region, and terminator is shown in SEQ ID NO:1.
- the gene has been designated GAPI those skilled in the art will recognize that SEQ ID NO:1 represents a single allele of the P . methanolica GAP1 gene and that other functional alleles (allelic variants) are likely to exist, and that allelic variation may include nucleotide changes in the promoter region, coding region, or terminator region.
- the GAPDH open reading frame begins with the methionine codon (ATG) at nucleotides 1733 - 1735.
- the transcription promoter is located upstream of the ATG.
- Gene expression experiments showed that a functional promoter was contained within the ca. 900 nucleotide 5'-flanking region of the GAP1 gene.
- Analysis of this promoter sequence revealed the presence of a number of sequences homologous to Saccharomyces cerevisiae promoter elements. These sequences include a concensus TATAAA box at nucleotides 1584 to 1591, a consensus Rap1p binding site (Graham and Chambers, Nuc . Acids Res .
- Preferred portions of the sequence shown in SEQ ID NO:1 for use within the present invention as transcription promoters include segments comprising at least 900 contiguous nucleotides of the 5' non-coding region of SEQ ID NO:1, and preferably comprising nucleotide 810 to nucleotide 1724 of the sequence shown in SEQ ID NO:1.
- Promoter sequences of the present invention can thus include the sequence of SEQ ID NO:1 through nucleotide 1732 in the 3' direction and can extend to or beyond nucleotide 232 in the 5' direction.
- the promoter used within an expression DNA construct will generally not exceed 1.5 kb in length, and will often not exceed 1.0 kb in length.
- sequence of SEQ ID NO:1 from nucleotide 810 to 1724 provides a functional transcription promoter.
- additional nucleotides can be removed from either or both ends of this sequence and the resulting sequence tested for promoter function by joining it to a sequence encoding a protein, preferably a protein for which a convenient assay is readily available.
- the GAP1 promoter be substantially free of GAP1 gene coding sequence, which begins with nucleotide 1733 in SEQ ID NO:1.
- the term "substantially free of GAP1 gene coding sequence” means that the promoter DNA includes not more than 15 nucleotides of the GAP1 coding sequences, preferably not more than 10 nucleotides, and more preferably not more than 3 nucleotides.
- the GAP1 promoter is provided free of coding sequence of the P. methanolica GAP1 gene.
- GAP1 gene fragment that includes the initiation ATG (nucleotides 1733 to 1735) of SEQ ID NO:1 can be operably linked to a heterologous coding sequence that lacks an ATG, with the GAP1 ATG providing for initiation of translation of the heterologous sequence.
- additional GAP1 coding sequences can also be included, whereby a fusion protein comprising GAP1 and heterologous amino acid sequences is produced.
- Such a fusion protein may comprise a cleavage site to facilitate separation of the GAP1 and heterologous sequences subsequent to translation.
- the present invention also provides transcription terminator sequences derived from the 3' non-coding region of the P. methanolica GAP1 gene.
- a consensus transcription termination sequence (Chen and Moore, Mol. Cell. Biol . 12 :3470-3481, 1992) is at nucleotides 2774 to 2787 of SEQ ID NO:1.
- transcription terminator gene segments of at least about 60 bp in length. Longer segments, for example at least 90 bp in length or about 200 bp in length, will often be used. These segments comprise the termination sequence disclosed above, and may have as their 5' termini nucleotide 2735 of SEQ ID NO:1.
- the transcription terminator segment that is provided in an expression vector can include at its 5' terminus the TAA translation termination codon at nucleotides 2732-2734 of SEQ ID NO:1 to permit the insertion of coding sequences that lack a termination codon.
- DNA vectors including expression vectors, commonly contain a selectable marker and origin of replication that function in a bacterial host (e.g., E . coli ) to permit the replication and amplification of the vector in a prokaryotic host.
- bacterial host e.g., E . coli
- these prokaryotic elements can be removed from a vector before it is introduced into an alternative host. For example, such prokaryotic sequences can be removed by linearization of the vector prior to its introduction into a P. methanolica host cell.
- expression vectors comprise a first DNA segment comprising at least a portion of the sequence of SEQ ID NO:1 that is a functional transcription promoter operably linked to a second DNA segment encoding a protein of interest.
- the vector will further comprise a secretory signal sequence operably linked to the first and second DNA segments.
- the secretory signal sequence may be that of the protein of interest, or may be derived from another secreted protein, preferably a secreted yeast protein.
- a preferred such yeast secretory signal sequence is the S . cerevisiae alpha-factor ( MF ⁇ 1) pre-pro sequence (disclosed by Kurjan et al., U.S. Patent No. 4,546,082 and Brake, U.S. Patent No. 4,870,008).
- expression vectors comprise a DNA segment comprising a portion of SEQ ID NO:1 that is a functional transcription terminator operably linked to an additional DNA segment encoding a protein of interest.
- the P. methanolica GAP1 promoter and terminator sequences are used in combination, wherein both are operably linked to a DNA segment encoding a protein of interest within an expression vector.
- Expression vectors of the present invention further comprise a selectable marker to permit identification and selection of P . methanolica cells containing the vector.
- Selectable markers provide for a growth advantage of cells containing them. The general principles of selection are well known in the art.
- the selectable marker is preferably a P. methanolica gene.
- Commonly used selectable markers are genes that encode enzymes required for the synthesis of amino acids or nucleotides. Cells having mutations in these genes cannot grow in media lacking the specific amino acid or nucleotide unless the mutation is complemented by the selectable marker. Use of such "selective" culture media ensures the stable maintenance of the heterologous DNA within the host cell.
- An exemplary selectable marker of this type for use in P . methanolica is a P.
- methanolica ADE2 gene which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21). See, Raymond, U.S. Patent No. 5,736,383.
- the ADE2 gene when transformed into an ade2 host cell, allows the cell to grow in the absence of adenine.
- the coding strand of a representative P. methanolica ADE2 gene sequence is shown in SEQ ID NO:2. The sequence illustrated includes 1006 nucleotides of 5' non-coding sequence and 442 nucleotides of 3' non-coding sequence, with the initiation ATG codon at nucleotides 1007-1009.
- a DNA segment comprising nucleotides 407-2851 is used as a selectable marker, although longer or shorter segments could be used as long as the coding portion is operably linked to promoter and terminator sequences.
- a dominant selectable marker which provides a growth advantage to wild-type cells.
- Typical dominant selectable markers are genes that provide resistance to antibiotics, such as neomycin-type antibiotics (e.g., G418), hygromycin B, and bleomycin/phleomycin-type antibiotics (e.g., ZeocinTM; available from Invitrogen Corporation, San Diego, CA).
- An exemplary dominant selectable marker for use in P . methanolica is the Sh bla gene, which inhibits the activity of ZeocinTM.
- P. methanolica cells as a host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565; and U.S. Patents Nos. 5,716,808, 5,736,383, 5,854,039, and 5,888,768.
- Expression vectors for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation.
- the entire expression segment of the plasmid can be flanked at both ends by host DNA sequences (e.g., AUG1 3' sequences). Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into P. methanolica cells. It is preferred to transform P . methanolica cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant ( ⁇ ) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.
- ⁇ time constant
- Integrative transformants are preferred for use in protein production processes. Such cells can be propagated without continuous selective pressure because DNA is rarely lost from the genome. Integration of DNA into the host chromosome can be confirmed by Southern blot analysis. Briefly, transformed and untransformed host DNA is digested with restriction endonucleases, separated by electrophoresis, blotted to a support membrane, and probed with appropriate host DNA segments. Differences in the patterns of fragments seen in untransformed and transformed cells are indicative of integrative transformation. Restriction enzymes and probes can be selected to identify transforming DNA segments (e.g., promoter, terminator, heterologous DNA, and selectable marker sequences) from among the genomic fragments.
- transforming DNA segments e.g., promoter, terminator, heterologous DNA, and selectable marker sequences
- More accurate analysis of expression levels can be obtained by culturing cells in liquid media and analyzing conditioned media or cell lysates, as appropriate. Methods for concentrating and purifying proteins from media and lysates will be determined in part by the protein of interest. Such methods are readily selected and practiced by the skilled practitioner.
- Vacuolar protease activity is measured using any of several known assays, such as those developed for S. cerevisiae and disclosed by Jones, Methods Enzymol. 194 :428-453, 1991.
- One such assay is the APNE overlay assay, which detects activity of carboxypeptidase Y (CpY). See, Wolf and Fink, J. Bact . 123 :1150-1156, 1975.
- the APNE assay is indicative of vacuolar protease activity in general.
- the APNE overlay assay detects the carboxypeptidase Y-mediated release of ⁇ -naphthol from N-acetyl-phenylalanine- ⁇ -naphthyl-ester (APNE), which results in the formation of an isoluble red dye by the reaction of the ⁇ -naphthol with the diazonium salt Fast Garnet GBC.
- Cells growing on assay plates e.g., YEPD plates
- assay plates e.g., YEPD plates
- RxM is prepared by combining 0.175 g agar, 17.5 ml H 2 O, and 5 ml 1 M Tris-HCl pH 7.4, microwaving the mixture to dissolve the agar, cooling to ⁇ 55°C, adding 2.5 ml freshly made APNE (2 mg/ml in dimethylformamide) (Sigma Chemical Co., St. Louis, MO), and, immediately before assay, 20 mg Fast Garnet GBC salt (Sigma Chemical Co.). The overlay is allowed to solidify, and color development is observed. Wild-type colonies are red, whereas CPY deletion strains are white.
- Carboxypeptidase Y activity can also be detected by the well test, in which cells are distributed into wells of a microtiter test plate and incubated in the presence of N -benzoyl-L-tyrosine p -nitroanilide (BTPNA) and dimethylformamide. The cells are permeabilized by the dimethylformamide, and CpY in the cells cleaves the amide bond in the BTPNA to give the yellow product p-nitroaniline. Assays for CpY will detect any mutation that reduces protease activity so long as that activity ultimately results in the reduction of CpY activity.
- BTPNA N -benzoyl-L-tyrosine p -nitroanilide
- P. methanolica cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors.
- a suitable culture medium for P. methanolica is YEPD (2% D-glucose, 2% BactoTM Peptone (Difco Laboratories, Detroit, MI), 1% BactoTM yeast extract (Difco Laboratories), 0.004% adenine, 0.006% L-leucine).
- a P. methanolica strain For large-scale culture, one to two colonies of a P. methanolica strain can be picked from a fresh agar plate (e.g, YEPD agar) and suspended in 250 ml of YEPD broth contained in a two-liter baffled shake flask. The culture is grown for 16 to 24 hours at 30°C and 250 rpm shaking speed. Approximately 50 to 80 milliliters of inoculum are used per liter starting fermentor volume (5 - 8% v/v inoculum).
- a preferred fermentation medium is a soluble medium comprising glucose as a carbon source, inorganic ammonia, potassium, phosphate, iron, and citric acid.
- a "soluble medium” is a medium that does not contain visible precipitation.
- the medium lacks phosphate glass (sodium hexametaphosphate).
- a preferred medium is prepared in deionized water and does not contain calcium sulfate.
- the medium lacks polypeptides or peptides, such as yeast extracts.
- acid hydrolyzed casein e.g., casamino acids or amicase
- casein can be added to the medium if desired.
- An illustrative fermentation medium is prepared by mixing the following compounds: (NH 4 ) 2 SO 4 (11.5 grams/liter), K 2 HPO 4 (2.60 grams/liter), KH 2 PO 4 (9.50 grams/liter), FeSO 4 •7H 2 O (0.40 grams/liter), and citric acid (1.00 gram/liter). After adding distilled, deionized water to one liter, the solution is sterilized by autoclaving, allowed to cool, and then supplemented with the following: 60% (w/v) glucose solution (47.5 milliliters/liter), 10x trace metals solution (20.0 milliliters/liter), 1 M MgSO 4 (20.0 milliliters/liter), and vitamin stock solution (2.00 milliliters/liter).
- the 10x trace metals solution contains FeSO 4 ⁇ 7H 2 O (100 mM), CuSO 4 •5H 2 O (2 mM), ZnSO 4 ⁇ 7H 2 O (8 mM), MnSO 4 ⁇ H 2 O (8 mM), CoCl 2 ⁇ 6H 2 O (2 mM), Na 2 MoO 4 ⁇ 2H 2 O (1 mM), H 3 BO 3 (8 mM), KI (0.5 mM), NiSO 4 ⁇ 6H 2 O (1 mM), thiamine (0.50 grams/liter), and biotin (5.00 milligrams/liter).
- the vitamin stock solution contains inositol (47.00 grams/liter), pantothenic acid (23.00 grams/liter), pyrodoxine (1.20 grams/liter), thiamine (5.00 grams/liter), and biotin (0.10 gram/liter).
- inositol 47.00 grams/liter
- pantothenic acid 23.00 grams/liter
- pyrodoxine 1.20 grams/liter
- thiamine 5.00 grams/liter
- biotin (0.10 gram/liter).
- ammonium sulfate can be substituted with ammonium chloride, or the amount of ammonium sulfate can be varied, for example, from about 11 to about 22 grams/liter.
- the pH of the medium is typically adjusted to pH 4.5 by addition of 10% H 3 PO 4 . Generally, about 10 milliliters/liter are added, and no additional acid addition will be required. During fermentation, the pH is maintained between about 3.5 to about 5.5, or about 4.0 to about 5.0, depending on protein produced, by addition of 5 N NH 4 OH.
- An illustrative fermentor is a BIOFLO 3000 fermentor system (New Brunswick Scientific Company, Inc.; Edison, NJ). This fermentor system can handle either a six-liter or a fourteen-liter fermentor vessel. Fermentations performed with the six-liter vessel are prepared with three liters of medium, whereas fermentations performed with the fourteen-liter vessel are prepared with six liters of medium.
- the fermentor vessel operating temperature is typically set to 30°C for the course of the fermentation, although the temperature can range between 27-31°C depending on the protein expressed.
- the fermentation is initiated in a batch mode. The glucose initially present is often used by approximately 10 hours elapsed fermentation time (EFT), at which time a glucose feed can be initiated to increase the cell mass.
- EFT elapsed fermentation time
- An illustrative glucose feed contains 900 milliliters of 60% (w/v) glucose, 60 milliliters of 50% (w/v) (NH 4 ) 2 SO 4 , 60 milliliters of 10x trace metals solution, and 30 milliliters of 1 M MgSO 4 .
- P. methanolica fermentation is robust and requires high agitation, aeration, and oxygen sparging to maintain the percentage dissolved oxygen saturation above 30%. The percentage dissolved oxygen should not drop below 15% for optimal expression and growth.
- the biomass typically reaches about 30 to about 80 grams dry cell weight per liter at 48 hours EFT.
- Proteins produced according to the present invention are recovered from the host cells using conventional methods. If the protein is produced intracellulary, the cells are harvested (e.g., by centrifugation) and lysed to release the cytoplasmic contents. Methods of lysis include enzymatic and mechanical disruption. The crude extract is then fractionated according to known methods, the specifics of which will be determined for the particular protein of interest. Secreted proteins are recovered from the conditioned culture medium using standard methods, also selected for the particular protein. See, in general, Scopes, Protein Purification: Principles and Practice , Springer-Verlag, New York, 1994.
- the materials and methods of the present invention can be used to produce proteins of research, industrial, or pharmaceutical interest.
- proteins include enzymes, such as lipases, cellulases, and proteases; enzyme inhibitors, including protease inhibitors; growth factors such as platelet derived growth factor (PDGF), fibroblast growth factors (FGF), epidermal growth factor (EGF), vascular endothelial growth factors (VEGFs); glutamic acid decarboxylase (GAD); cytokines, such as erythropoietin, thrombopoietin, colony stimulating factors, interleukins, and interleukin antagonists; hormones, such as insulin, proinsulin, leptin, and glucagon; and receptors, including growth factor receptors, which can be expressed in truncated form (“soluble receptors”) or as fusion proteins with, for example, immunoglobulin constant region sequences.
- PDGF platelet derived growth factor
- FGF fibroblast growth factors
- EGF epi
- the materials and methods of the present invention can be used to produce unglycosylated pharmaceutical proteins.
- Yeast cells including P. methanolica cells, produce glycoproteins with carbohydrate chains that differ from their mammalian counterparts. Mammalian glycoproteins produced in yeast cells may therefore be regarded as "foreign" when introduced into a mammal, and may exhibit, for example, different pharmacokinetics than their naturally glycosylated counterparts.
- PCR primers were designed from an alignment of the coding regions of GAPDH genes of Saccharomyces cerevisiae , Kluyveromyces lactis , and mouse. The primers were then used to amplify P . methanolica genomic DNA. An amplified sequence 608 bp long was recovered and was found to have 78.1% homology to the corresponding S . cerevisiae GAPDH gene sequence.
- a P. methanolica genomic library was constructed in the vector pRS426 (Christianson et al., Gene 110 :119-122, 1992), a shuttle vector comprising 2 ⁇ and S. cerevisiae URA3 sequences, allowing it to be propagated in S. cerevisiae .
- Genomic DNA was prepared from strain CBS6515 according to standard procedures. Briefly, cells were cultured overnight in rich media, spheroplasted with zymolyase, and lysed with SDS. DNA was precipitated from the lysate with ethanol and extracted with a phenol/chloroform mixture, then precipitated with ammonium acetate and ethanol.
- the library was screened by PCR using sense (ZC11,733; SEQ ID NO:5) and antisense (ZC11,734; SEQ ID NO:6) primers designed from the sequenced region of the P. methanolica GAPDH gene fragment.
- the PCR reaction mixture was incubated for one minute at 94°C; followed by 34 cycles of 94°C, one minute, 52°C, 45 seconds, 72°C, two minutes; and a termination cycle of 94°C, one minute, 54°C, one minute, 72°C, eleven minutes.
- positive pools were identified and broken down to individual colonies.
- a single colony with a pRS426 plasmid containing the P. methanolica GAPDH gene as its insert was isolated.
- the orientation of the GAPDH gene and the length of the 5' and 3' flanking sequences in the insert were deduced by DNA sequencing (SEQ ID NO:1). This gene was designated GAP1 .
- a plasmid containing the GAP1 gene, designated pGAPDH, has been deposited as an E. coli strain MC1061 transformant with American Type Culture Collection, Manassas, VA under the terms of the Budapest Treaty. The deposited strain has been assigned the designation PTA-3 and a deposit date of May 4, 1999.
- Plasmid pCZR133 comprises the P. methanolica AUG1 promoter and terminator flanking a multiple cloning site, and a P. methanolica ADE2 selectable marker.
- the GAP1 promoter (nucleotides 810 to 1724 of SEQ ID NO:1) was amplified by PCR using primers that introduced a Not I site at the 5' end (SEQ ID NO:7; ZC12,586), and Eco RI and Bam HI sites at the 3' end (SEQ ID NO:8; ZC12,565).
- the reaction mixture was incubated for one minute at 94°C; followed by 34 cycles of 94°C, one minute, 52°C, one minute, 72°C, three minutes; and a termination cycle of 94°C, one minute, 54°C, seven minutes, 72°C, 23 minutes.
- the amplified promoter was then blunt-end ligated into a phagemid vector (pBluescript®; Stratagene, La Jolla, CA). The orientation of the promoter in the vector was determined by restriction analysis. The promoter was isolated as a Not I - Bam HI fragment. Plasmid pCZR133 was digested with Not I and Bam HI, and the digest was electrophoresed on a gel. Two fragments, the Ade2/termination fragment and the pUC fragment, were recovered. The pUC fragment was dephosphorylated. The two vector fragments and the promoter were joined in a three-part ligation. The resulting plasmid was designated pBM/GAP (Fig. 1).
- a second vector, pTAP76 (Fig. 2) was constructed.
- This vector comprises the GAP1 promoter, ⁇ -factor prepro sequence, a SmaI. cleavage site, the AUG1 terminator, the ADE2 selectable marker, and AUG1 3' non-coding sequence cloned into a pRS316 (Sikorski and Hieter, Genetics 122 :19-27, 1989) backbone.
- the pTAP76 vector is linearized at the SmaI site and combined with a DNA fragment of interest and double-stranded recombination linkers in S . cerevisiae , whereby the fragment of interest is joined to the vector by homologous recombination as disclosed by Raymond et al., BioTechniques 26 :134-141, 1999.
- heterologous genes from the GAP1 promoter was tested using LacZ and GFP (green fluorescent protein) reporter genes. These genes were prepared as Eco RI-Bam HI fragments, and were individually ligated to Eco RI, Bam HI-digested pBM/GAP. The resulting plasmids were transformed into P. methanolica host cells, and the cells were grown in both glucose and methanol fermentation conditions. Both reporter genes were expressed under both conditions, showing that the cloned GAP1 promoter can be used to constitutively express heterologous genes in P. methanolica cells.
- PEP4 and PRB1 genes were identified and disrupted.
- PEP4 and PRB1 sequences were amplified by PCR in reaction mixtures containing 100 pmol of primer DNA, 1X buffer as supplied (Boehringer Mannheim, Indianapolis, IN), 250 ⁇ M dNTPs, 1-100 pmol of template DNA, and 1 unit of Taq polymerase in a reaction volume of 100 ⁇ l.
- the DNA was amplified over 30 cycles of 94°C, 30 seconds; 50°C, 60 seconds; and 72°C, 60 seconds.
- DNA sequencing of a portion of this genomic clone revealed an open reading frame encoding a polypeptide (SEQ ID NO:12) with 70% amino acid identity with proteinase A from S. cerevisiae .
- Primers for the identification of P. methanolica PRB1 were designed on the basis of alignments between the PRB1 genes of S. cerevisiae (Moehle et al., Mol. Cell . Biol . 7 :4390-4399, 1987), P. pastoris (Gleeson et al., U.S. Pat. No. 5,324,660), and Kluyveromyces lactis (Fleer et al., WIPO Publication WO 94/00579).
- One primer set, ZC9126 (SEQ ID NO:13) and ZC9741 (SEQ ID NO:14) amplified a ca. 400 bp fragment from genomic DNA (SEQ ID NO:15).
- This product was sequenced and found to encode a polypeptide (SEQ ID NO:16) with 70% amino acid identity with proteinase B from S. cerevisiae .
- the PRB primer set was then used to identify a genomic clone encompassing the P. methanolica PRB1 gene.
- Deletion mutations in the P. methanolica PEP4 and PRB1 genes were generated using available restriction enzyme sites. The cloned genes were restriction mapped. The pep4 ⁇ allele was created by deleting a region of approximately 500 bp between BamHI and NcoI sites and including nucleotides 1 through 393 the sequence shown in SEQ ID NO:11. The prb1 ⁇ allele was generated by deleting a region of approximately 1 kbp between NcoI and EcoRV sites and including the sequence shown in SEQ ID NO:15.
- the cloned PEP4 and PRB1 genes were subcloned into pCZR139, a phagemid vector (pBluescript® II KS(+), Stratagene, La Jolla, CA) that carried a 2.4 kb SpeI ADE2 insert, to create the deletions.
- pCZR139 a phagemid vector
- the unique BamHI site in pCZR139 was eliminated by digestion, fill-in, and religation.
- the vector was then linearized by digestion with EcoRI and HindIII, and a ca. 4 kb EcoRI - HindIII fragment spanning the PEP4 gene was ligated to the linearized vector to produce plasmid pCZR142.
- 500-bp deletion was then produced by digesting pCZR142 with BamHI and NcoI, filling in the ends, and religating the DNA to produce plasmid pCZR143.
- the PRB1 gene ( ⁇ 5 kb XhoI - BamHI fragment) was subcloned into pCZR139, and an internal EcoRV - NcoI fragment, comprising the sequence shown in SEQ ID NO:15, was deleted to produce plasmid pCZR153.
- Plasmid pCZR143 was linearized with Asp718, which cut at a unique site.
- the linearized plasmid was introduced into the P . methanolica PMAD11 strain (an ade2 mutant generated as disclosed in U.S. Patent No. 5,736,383).
- Transformants were grown on ADE DS (Table 1) to identify Ade + transformants. Two classes of white, Ade + transformants were analyzed. One class arose immediately on the primary transformation plate; the scond became evident as rapidly growing white papillae on the edges of unstable, pink transformant colonies.
- Southern blotting was used to identify transformants that had undergone the desired homologous integration event. 100 ⁇ l of cell paste was scraped from a 24-48 hour YEPD plate and washed in 1 ml water. Washed cells were resuspended in 400 ⁇ l of spheroplast buffer (1.2 M sorbitol, 10 mM Na citrate pH 7.5, 10 mM EDTA, 10 mM DTT, 1 mg/ml zymolyase 100T) and incubated at 37°C for 10 minutes.
- spheroplast buffer 1.2 M sorbitol, 10 mM Na citrate pH 7.5, 10 mM EDTA, 10 mM DTT, 1 mg/ml zymolyase 100T
- the PRB1 gene was then deleted from PMAD15 essentially as described above by transformation with plasmid pCZR153. Blots were probed with PCR-generated probes for internal portions of the PRB1 and ADE2 genes.
- the PRB1 probe was generated by subcloning a 2.6 kb ClaI - SpeI fragment of PRB1 into the phagemid vector pBluescript® II KS(+) to produce pCZR150, and amplifying the desired region by PCR using primers ZC447 (SEQ ID NO:17) and ZC976 (SEQ ID NO:18).
- the ADE2 probe was generated by amplifying the ADE2 gene in pCZR139 with primers ZC9079 (SEQ ID NO:19) and ZC9080 (SEQ ID NO:20). The resulting ade2-11 pep4 ⁇ prb1 ⁇ strain was designated PMAD16.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Raymond, Christopher K.
Vanaja, Erica
Miller, Brady G.
Sloan, James S.
<151> 1999-06-24
<211> 4409
<212> DNA
<213> Pichia methanolica
<221> CDS
<222> (1733)...(2734)
<211> 3077
<212> DNA
<213> Pichia methanolica
<211> 19
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC11, 356
<211> 18
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC11,357
<211> 20
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC11,733
<211> 20
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC11,734
<211> 29
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC12,586
<211> 45
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC12,565
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9118
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9464
<222> (1)...(17)
<223> n = A.T.C or G
<211> 421
<212> DNA
<213> Pichia methanolica
.<221> CDS
<222> (2)...(421)
<211> 140
<212> PRT
<213> Pichia methanolica
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9126
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9741
<222> (1)...(17)
<223> n = A,T,C or G
<211> 368
<212> DNA
<213> Pichia methanolica
<221> CDS
<222> (1)...(366)
<222> (1)...(368)
<223> n = A,T,C or G
<211> 122
<212> PRT
<213> Pichia methanolica
<221> VARIANT
<222> (1)...(122)
<223> Xaa = Any Amino Acid
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC447
<211> 18
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC976
<211> 39
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9079
<211> 38
<212> DNA
<213> Artificial Sequence
<223> Oligonucleotide primer ZC9080
Claims (5)
- A DNA construct comprising the following operably linked elements:a first DNA segment comprising at least a portion of the sequence of SEQ ID NO: 1 from nucleotide 733 to nucleotide 1732, wherein said portion is a functional transcription promoter;a second DNA segment encoding a protein of interest other than a Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase;a third DNA segment comprising a transcription terminator; anda secretory signal sequence operably linked to the first and second DNA segments.
- The DNA construct of claim 1, wherein the secretory signal sequence is a Saccharomyces cerevisiae alpha-factor pre-pro sequence.
- The DNA construct of claim 1 wherein said third DNA segment comprises a transcription terminator of a Pichia methanolica Alcohol Utilisation Gene 1 or Glyceraldehyde 3-Phosphate Dehydrogenase gene.
- The DNA construct of claim 3, wherein said terminator comprises nucleotides 2735 to 2795 of SEQ ID NO: 1.
- A DNA construct comprising the following operably linked elements:a first DNA segment comprising a Pichia methanolica gene transcription promoter;a second DNA segment encoding a protein of interest other than a Pichia methanolica protein; anda third DNA segment comprising nucleotides 2735 to 2795 of SEQ ID No.1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK00944702T DK1192263T3 (en) | 1999-06-24 | 2000-06-16 | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14070399P | 1999-06-24 | 1999-06-24 | |
US140703P | 1999-06-24 | ||
PCT/US2000/016671 WO2000078978A1 (en) | 1999-06-24 | 2000-06-16 | Pichia methanolica glyceraldehyde 3-phosphate dehydrogenase 1 promoter and terminator |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1192263A1 EP1192263A1 (en) | 2002-04-03 |
EP1192263B1 true EP1192263B1 (en) | 2004-09-15 |
Family
ID=22492440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00944702A Expired - Lifetime EP1192263B1 (en) | 1999-06-24 | 2000-06-16 | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator |
Country Status (11)
Country | Link |
---|---|
US (1) | US6613547B1 (en) |
EP (1) | EP1192263B1 (en) |
JP (1) | JP2003503030A (en) |
AT (1) | ATE276372T1 (en) |
AU (1) | AU5876300A (en) |
CA (1) | CA2397494A1 (en) |
DE (1) | DE60013829T2 (en) |
DK (1) | DK1192263T3 (en) |
ES (1) | ES2231217T3 (en) |
MX (1) | MXPA02000160A (en) |
WO (1) | WO2000078978A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4464269B2 (en) | 2002-04-26 | 2010-05-19 | 協和発酵キリン株式会社 | Methylotrophic yeast producing mammalian sugar chains |
US7259255B2 (en) * | 2003-06-25 | 2007-08-21 | E. I. Du Pont De Nemours And Company | Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast |
WO2006065967A2 (en) * | 2004-12-15 | 2006-06-22 | General Atomics | Allosteric enzyme coupled immunoassay (aecia) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2000101A1 (en) * | 1988-12-22 | 1990-06-22 | Mary E. Digan | Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene |
DK0438200T3 (en) * | 1990-01-16 | 2002-11-11 | Ct Ingenieria Genetica Biotech | Method for expression of heterologous genes in the yeast Pichia pastoris, expression vectors and transformed microorganisms |
EP0889966A1 (en) * | 1995-11-09 | 1999-01-13 | ZymoGenetics, Inc. | Compositions and methods for producing heterologous polypeptides in pichia methanolica |
MX9605082A (en) * | 1996-10-24 | 1998-04-30 | Univ Autonoma De Nuevo Leon | Genetically modified methylotrophic yeasts for human growth hormone secretion production. |
WO1999014347A1 (en) * | 1997-09-15 | 1999-03-25 | Zymogenetics, Inc. | PROTEASE-DEFICIENT STRAINS OF $i(PICHIA METHANOLICA) |
US6258559B1 (en) * | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
-
2000
- 2000-06-16 DE DE60013829T patent/DE60013829T2/en not_active Expired - Fee Related
- 2000-06-16 CA CA002397494A patent/CA2397494A1/en not_active Abandoned
- 2000-06-16 WO PCT/US2000/016671 patent/WO2000078978A1/en active IP Right Grant
- 2000-06-16 AT AT00944702T patent/ATE276372T1/en not_active IP Right Cessation
- 2000-06-16 US US09/786,606 patent/US6613547B1/en not_active Expired - Fee Related
- 2000-06-16 DK DK00944702T patent/DK1192263T3/en active
- 2000-06-16 JP JP2001505718A patent/JP2003503030A/en active Pending
- 2000-06-16 MX MXPA02000160A patent/MXPA02000160A/en unknown
- 2000-06-16 ES ES00944702T patent/ES2231217T3/en not_active Expired - Lifetime
- 2000-06-16 EP EP00944702A patent/EP1192263B1/en not_active Expired - Lifetime
- 2000-06-16 AU AU58763/00A patent/AU5876300A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1192263A1 (en) | 2002-04-03 |
DK1192263T3 (en) | 2005-01-31 |
DE60013829T2 (en) | 2005-09-22 |
DE60013829D1 (en) | 2004-10-21 |
CA2397494A1 (en) | 2000-12-28 |
ES2231217T3 (en) | 2005-05-16 |
US6613547B1 (en) | 2003-09-02 |
MXPA02000160A (en) | 2003-10-14 |
JP2003503030A (en) | 2003-01-28 |
WO2000078978A1 (en) | 2000-12-28 |
AU5876300A (en) | 2001-01-09 |
ATE276372T1 (en) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU712650B2 (en) | Compositions and methods for producing heterologous polypeptides in pichia methanolica | |
US5955349A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
FI107939B (en) | Kluyveromyces as a host strain | |
US5716808A (en) | Genetic engineering of pichia methanolica | |
AU708572B2 (en) | Preparation of (pichia methanolica) auxotrophic mutants | |
US5736383A (en) | Preparation of Pichia methanolica auxotrophic mutants | |
AU718510B2 (en) | Transformation of pichia methanolica | |
US6258559B1 (en) | Method for producing proteins in transformed Pichia | |
EP0213593B1 (en) | Repressible yeast promoters | |
WO1999007862A1 (en) | Novel pichia pastoris gene sequences and methods for their use | |
US6153424A (en) | Protease-deficient strains of Pichia methanolica | |
WO2000056903A2 (en) | IMPROVED METHODS FOR PRODUCING PROTEINS IN TRANSFORMED $i(PICHIA) | |
EP1192263B1 (en) | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator | |
US6001597A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
US6348331B1 (en) | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter | |
EP1210412A1 (en) | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter and terminator | |
WO1999014347A1 (en) | PROTEASE-DEFICIENT STRAINS OF $i(PICHIA METHANOLICA) | |
US6838555B2 (en) | Hansenula polymorpha mutants and process for the preparation of recombinant proteins using the same | |
EP1015577B8 (en) | Chromosomal mutagenesis in pichia methanolica | |
EP0946734B1 (en) | Preparation of pichia methanolica auxotrophic mutants | |
US6183953B1 (en) | Chromosomal mutagenesis in Pichia methanolica | |
EP0920525A1 (en) | TRANSFORMATION OF $i(PICHIA METHANOLICA) | |
MXPA00002567A (en) | Chromosomal mutagenesis in pichia methanolica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20020618 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040915 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60013829 Country of ref document: DE Date of ref document: 20041021 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041215 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041215 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20040915 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2231217 Country of ref document: ES Kind code of ref document: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20050531 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20050629 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20050708 Year of fee payment: 6 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20050725 Year of fee payment: 6 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: UNIVERSITY OF WASHINGTON Owner name: MILLER, BRADY G. Owner name: ZYMOGENETICS, INC. |
|
ET | Fr: translation filed | ||
26N | No opposition filed |
Effective date: 20050616 |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: ZYMOGENETICS, INC. EN MILLER, BRADY G. EN UNIVERSI Effective date: 20050803 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUEA Owner name: ZYMOGENETICS, INC. Free format text: ZYMOGENETICS, INC.#1201 EASTLAKE AVENUE EAST#SEATTLE, WA 98102 (US) $ MILLER, BRADY G.#6061 VILLAGE BEND DRIVE 1816#DALLAS, TX 75206 (US) $ SLOAN, JAMES S.#6423 NORTHEAST 154TH STREET#KENMORE, WA 98028 (US) -TRANSFER TO- ZYMOGENETICS, INC.#1201 EASTLAKE AVENUE EAST#SEATTLE, WA 98102 (US) $ UNIVERSITY OF WASHINGTON#4311 11TH AVENUE NE#SEATTLE, WA 98105 (US) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060617 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060630 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ |
|
NLS | Nl: assignments of ep-patents |
Owner name: BRADY G. MILLER Effective date: 20060711 Owner name: UNIVERSITY OF WASHINGTON Effective date: 20060711 Owner name: ZYMOGENETICS, INC. Effective date: 20060711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070101 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20070102 Year of fee payment: 7 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20070101 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20060617 |
|
BECA | Be: change of holder's address |
Owner name: *ZYMOGENETICS INC. Effective date: 20050926 Owner name: *UNIVERSITY OF WASHINGTON1201 EASTLAKE AVENUE EAST Effective date: 20050926 Owner name: 4311 11TH AVENUE NE, SUITE 500, SEATTLE, WASHINGTO Effective date: 20050926 |
|
BECH | Be: change of holder |
Owner name: *UNIVERSITY OF WASHINGTON Effective date: 20050926 Owner name: *ZYMOGENETICS INC. Effective date: 20050926 |
|
BERE | Be: lapsed |
Owner name: *UNIVERSITY OF WASHINGTON Effective date: 20060630 Owner name: *ZYMOGENETICS INC. Effective date: 20060630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050215 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070702 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20090626 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20090625 Year of fee payment: 10 Ref country code: AT Payment date: 20090603 Year of fee payment: 10 Ref country code: FR Payment date: 20090617 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20090625 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20090625 Year of fee payment: 10 Ref country code: DE Payment date: 20090629 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20100616 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110101 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100616 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100616 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100616 |